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An international series of pulmonary retransplantat ion was updated to 
identify the predictors of outcome and the prevalence and recurrence rate 
of obliterative bronchiolitis after operation. The study cohort included 139 
patients who underwent retransplantat ion i  34 institutions in North 
America and Europe between 1985 and 1994. Eighty patients underwent 
retransplantat ion because of obliterative bronchiolitis, 34 because of acute 
graft failure, 13 because of intractable airway complications, 8 because of 
acute rejection, and 4 because of other indications. Survivors were followed 
up for a median of 630 days, with 48 patients alive at 1 year, 30 at 2 years, 
and 16 at 3 years after retransplantation. Actuarial survival was 65% -+ 4% 
at 1 month, 54% - 4% at 3 months, 45% + 4% at 1 year, 38% - 5% at 2 
years, and 36% -+ 5% at 3 years; nonetheless, of 90-day postoperative 
survivors, 65% - 6% were alive 3 years after retransplantation. Life-table 
and univariate Cox analysis revealed that more recent year of retransplan- 
tation (p = 0.009), identical match of ABO blood group (p = 0.01), absence 
of a donor-recipient cytomegalovirus mismatch (p = 0.04), and being 
ambulatory immediately before retransplantat ion (p = 0.04) were associ- 
ated with survival. By multivariate Cox analysis, being ambulatory before 
retransplantat ion was the most significant predictor of survival (p = 0.008), 
followed by reoperation in Europe (p = 0.044). Complete pulmonary 
function tests were done yearly in every survivor of retransplantat ion a d 
bronchiolitis obliterans syndrome stages were assigned. Eleven percent of 
patients were in stage 3 at 1 year, 20% at 2 years, and 25% at 3 years after 
retransplantation. Values of forced expiratory volume in 1 second de- 
creased from 1.89 - 0.13 L early after retransplantat ion to 1.80 - 0.15 L 
at 1 year and 1.54 +- 0.16 L at 2 years (p = 0.006, year 2 versus baseline 
postoperative value). Most of this decrease occurred in patients who 
underwent retransplantat ion because of obliterative bronchiolitis, whereas 
the pulmonary function of patients who underwent retransplantation because 
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of other conditions did not significantly change. We conclude that survival 
after pulmonary retransplantation is improving. Optimal results can be 
obtained in patients who are ambulatory befbre retransplantation. Compared 
with recent data after primary lung transplantation, bronchiolitis obliterans 
syndrome does not appear to recur in an accelerated manner after retrans- 
plantation. As long as early mortality as a result of infection can be minimized, 
pulmonary retransplantation appears to offer a reasonable option in highly 
selected patients. (J THORAC CARDmVASC SURG 1995;110:1402-14) 
D uring the past decade lung transplantat ion has evolved into a successful therapy for patients 
with end-stage respiratory failure. Recently, donor 
and recipient selection, operat ive technique, and 
postoperat ive care have been refined, resulting in a 
significant improvement  in survival]  Despi te  these 
advances, the postoperat ive course of a significant 
number o:g patients is compl icated by early graft 
dysfunction, 2-4 art airway heal ing complication, 5' 6 or 
acute re ject ion] '  s Furthermore,  the development  of 
obl iterative bronchiol it is (OB) remains a threat to 
intermediate- term survivors of lung transplanta- 
tion. 9q2 On occasion, these complicat ions may 
prove so intractable that graft fai lure will ensue and 
the only possibil ity for cont inued survival rests with 
retransplantat ion.  Since 1988 an increasing number  
of pulmonary, retransplants have been per formed 
because of acute or chronic graft failure. ~3-21 The 
practice of pu lmonary retransplantat ion has raised 
controversy because of the shortage of lung grafts 
available for pr imary transplantat ion and the poor  
results in the early experience with these proce- 
dures. The pulmonary retransplant registry was es- 
tabl ished in 1991 to document,  in a large number  of 
patients, the outcome and predictors of survival 
after pulmonary retransplantation. 13 Recently, after 
additional :patient accrual and with increasing fol- 
low-up of retransplant recipients, the registry data 
were updated to determine the predictors of outcome 
and recurrence rate of OB after retransplantation. 
Patients and methods 
Since mid-1991 patients undergoing pulmonary retrans- 
plantation have been recruited to the pulmonary retrans- 
plant registry by means of a standardized study question- 
naire. These patients have been followed up prospectively 
with at leasl yearly updates of clinical status and pulmo- 
nary function. For the purposes of this report, the status of 
all study patients was determined in October 1994. Pa- 
tients who underwent retransplantation f r any indication 
were included in the study cohort. 
The 16 parameters listed in Tables I and II were 
analyzed in each patient. The chief outcome variables 
Table I. Association of recipient variables with 
survival after pulmonary retransplantation 
Univariate Multivariate 
analysis analysis 
Risk p Adjusted p 
Variable ratio Value risk ratio Value 
Age 
As a continuous variable * 0.984 t NS 
<40 vs. >40 yr 1.08 0.717 t NS 
Female sex 1.05 0.829 t NS 
Original diagnosis * 0.821 t NS 
Indication for * 0.468 t NS 
retransplantation 
Ambulatory before 0.59 0.045 0.46 0.008 
retransplant 
Ventilator support before 1.32 0.208 t NS 
retransplant 
Recipient CMV positMty 0.96 0.874 t NS 
Waiting time 
As a continuous variable * 0.240 t NS 
-<3 days vs. 4-14 days vs. * 0.259 t NS 
15-70 days vs. >70 days 
Interval between transplants 
As a continuous variable * 0.146 t NS 
-<4 wk vs. >4 wk-1 yr vs. * 0.144 t NS 
1-2 yr vs. >2 yr 
-<1 yr vs. >1 yr 1.14 0.553 t NS 
NS, Not significant on multivariate analysis; CMV, cytomegalovirus. 
*Risk ratio not calculated, because variable has more than two categories. 
tAdjusted risk ratio not calculated, because variable does not enter into 
multivariate model. 
included survival interval after retransplantation, cause of 
death, and pulmonary function test data. Study form 
results were incorporated into the pulmonary retransplant 
database with use of the FoxPro database management 
system (Microsoft Corporation, Redmond, Wash.) on a 
486DX2/66 MHz computer. Statistical analysis was per- 
formed with the SAS statistical package, version 6.04 
(SAS Institute Inc., Cary, N.C.). All data were expressed 
as mean plus or minus the standard error of the mean. 
Actuarial survival was calculated by the Kaplan-Meier 
method 22 and Cox proportional hazards methods 23 were 
used to determine which variables were associated with 
survival after pulmonary retransplantation. Variables ex- 
hibiting ap value less than 0.25 on univariate analysis were 
considered for entry into a multivariate model to deter- 
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Table II. Association of donor and operative 
variables with survival after pulmonary 
retransplantation 
Univariate Multivariate 
analysis analysis 
Adjusted 
Risk p risk p 
Variable ratio Value ratio Value 
Year of reoperation 
As a continuous variable * 0.009 t NS 
1985-1991 vs. 1992-1994 1.74 0.015 t NS 
Retransplant center 0.72 0.140 0.61 0.044 
(Europe vs. 
North America) 
Type of reoperation 
All 5 types * 0.795 t NS 
Old graft in situ vs. not 1.22 0.382 t NS 
Individual center experience 1.44 0.104 t NS 
(<5 vs. ->5 retransplants) 
Identical match of 0.55 0.015 t NS 
donor-recipient 
ABO blood group 
Donor CMV positivity 1.24 0.350 t NS 
Donor-recipient CMV 1.79 0.043 t NS 
mismatch 
NS, Not significant on multivariate analysis; CMV, cytomegalovirus. 
*Risk ratio not calculated, because variable has more than two categories. 
tAdjusted risk ratio not calculated, because variable does not enter into 
multivariate model. 
mine the independent predictors of survival after retrans- 
plantation. Furthermore, the risk ratio of each variable 
was expressed as a comparison ofsurvival between groups, 
with a value of 1.0 indicating no survival difference. 
A major focus of this report has been graft function and 
the recurrence of OB in the intermediate-term after 
retransplantation. The detection rate of histologic OB 
after retransplantation would be expected to vary among 
contributing centers, because of the different frequency of 
the performance ofpostoperative transbronchial biopsies. 
We therefore chose a functional, rather than a histologic 
definition of OB, which thus permitted the standardiza- 
tion of postoperative r sults among institutions. 11 Com- 
plete pulmonary function test data were obtained from 
every survivor of retransplantation at yearly intervals. 
Bronchiolitis obliterans syndrome (BOS) stages were des- 
ignated according to previously published criteria, based 
on values of forced expiratory volume in 1 second 
(FEV1).I, 11 The changes in absolute FEV 1 values at 1 and 
2 years after retransplantation were calculated for the 
entire study cohort, for single versus bilateral lung retrans- 
plant recipients, and for patients who underwent retrans- 
plantation because of OB versus those who underwent 
retransplantation because of other indications. Paired, 
two-tailed t tests were used to compare changes over time 
within each patient group, whereas unpaired, two-tailed t 
tests were used to contrast results between patient groups. 
Furthermore, contingency table analyses were used to com- 
pare the prevalence of and freedom from stages 1, 2, and 3 
BOS between patient groups at 1 and 2 years after etrans- 
plantation. Ap value less than 0.05 was deemed significant. 
Results 
Thirty-four lung transplant centers participated in
this study, including 19 from North America and 15 
from Europe. Participating institutions and the 
number of patients contributed by each center are 
listed in the appendix. A total of 139 patients have 
undergone retransplantation, i cluding 79 female 
and 60 male patients with a median age of 42 years 
(range 6 months to 62 years). Before the first 
transplantation procedure, 35% had a diagnosis of 
emphysema, 21% primary pulmonary hypertension 
or Eisenmenger's syndrome, 19% restrictive lung 
disease, 16% cystic fibrosis, and 9% miscellaneous 
conditions. The indications for retransplantation 
included OB in 80 cases, primary graft failure in 34 
cases, intractable airway complications in 13 cases, 
histologically confirmed severe acute rejection in 8 
cases, and other indications in 4 cases. Fifty-nine 
patients underwent repeat single-lung transplanta- 
tion, 37 on the ipsilateral side and 22 on the contralat- 
eral side. Thirty patients underwent repeat double- 
lung transplantation, 24 double-lung transplantation 
after a previous ingle-lung transplant, and 26 single- 
lung transplantation after a previous double-lung or 
heart-lung transplant. Patient follow-up was 100% 
complete, with up-to-date survival and pulmonary 
function test data available in every patient. 
Survival. The actuarial survival of all study pa- 
tients is shown in Fig. 1. Of the 139 retransplant 
recipients, 85 have died and 54 are still living. 
Actuarial survival was 65% ± 4% at 1 month, 
54% _+ 4% at 3 months, 45% _+ 4% at 1 year, 38% _+ 
5% at 2 years, and 36% _+ 5% at 3 years. Despite the 
significant patient attrition early after operation, 
65% + 6% of 90-day postoperative survivors were 
alive 3 years after retransplantation. The median 
follow-up in current survivors is 630 days (mean 
706 _+ 67 days, range 45 to 1781 days). Forty-eight 
patients have reached the first anniversary, 30 the 
second anniversary, 16 the third anniversary, and 4 
the fourth anniversary of retransplantation. 
The association of the 16 variables that were ana- 
lyzed in each patient with survival after retransplanta- 
tion is depicted in Tables I (recipient variables) and II 
(donor and operative variables). Survival was not 
statistically different according to the age, sex, or 
original diagnosis of the recipients. Similarly, survival 
did not differ according to the predominant indication 
for retransplantation (Fig. 2). Univariate Cox analysis 
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Fig. 2. Actuarial survival according to predominant indication for retransplantation; p = 0.468. 
has confirmed that survival after pulmonary retrans- 
plantation is improving (Table II). In particular, actu- 
arial survival has been significantly higher in patients 
who underwent retransplantation between 1992 and 
1994, as opposed to between 1985 and 1991 (Fig. 3). 
Effect of clinical condition before retransplanta- 
tion, waiting time, and interval between transplants 
on survival. Immediately before retransplanta- 
tion, only 29% of patients were ambulatory (able 
to walk 50 m with or without assistance). By 
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univariate and multivariate Cox analyses, ambu- 
latory patients had a significantly better survival 
than nonambulatory patients (Table I, Fig. 4). 
Before retransplantation, half of the patients 
were ventilator dependent whereas half required 
supplemental oxygen but not mechanical ventila- 
tion. There were no significant differences in 
survival according to the preoperative ventilator 
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status of the retransplant recipient (Table I). 
Neither the official waiting time for retransplan- 
tation nor the interval between transplant proce- 
dures had a significant impact on survival, regard- 
less of whether these variables were analyzed 
continuously or after the grouping of patients into 
approximately equal quartiles (Table I). 
Impact of the type of retransplant procedure and 
the retransplant center on survival. Actuarial sur- 
vival did not differ among patients undergoing the 
five different ypes of retransplant procedures (Ta- 
ble II). In 35% of cases, an old contralateral graft 
remained in situ after retransplantation, whereas in 
65% of  cases the old graft or grafts had been 
excised. As shown in Table II, survival was not 
significantly different according to whether an old 
graft remained in situ after retransplantation. 
Sixty-one patients underwent retransplantation 
in Europe and 78 in North America. In contradis- 
tinction to our previous report on retransplanta- 
tion for OB,  24 no  difference in survival was found 
between European and North American patients 
on univariate analysis (Table II). However, when 
adjusted for ambulatory status in the multivariate 
analysis, reoperation in Europe remained as a 
predictive variable (p = 0.044, adjusted risk ratio 
0.61). Six of the 19 North American centers and 3 
of the 15 European centers performed five or more 
pulmonary retransplant procedures. There was a trend 
toward improved survival in patients undergoing re- 
transplantation i centers with experience in at least 
five pulmonary retransplant procedures (Table II). 
Impact of donor-recipient ABO blood group and 
cytomegalovirus serologic status on survival. Sev- 
enty-eight percent of patients undergoing retransplan- 
tation received an ABO-identical graft at reoperation, 
whereas 22% received a graft that was ABO compat- 
ible, but not identical. Survival was significantly better 
in patients who received an ABO-identical graft (Fig. 
5). Neither donor nor recipient cytomegalovirus sero- 
logic status was predictive of survival after retransplan- 
tation; nonetheless, the 18 cases of cytomegalovirus 
mismatch (cytomegalovirus-positive donor, negative 
recipient) were associated with significantly decreased 
survival after retransplantation (Table II). 
Causes of death. As noted in previous reports 
from the registry, 13' 14, 24 infection was the predom- 
inant cause of death at all time intervals after 
retransplantation. I  this series, 48 of the 85 deaths 
(56%) were caused by opportunistic infection by 
viral, bacterial, or fungal organisms. Twenty-two 
percent of deaths were caused by acute failure of the 
second graft early after operation, 14% by recurrent 
OB, 4% by an airway complication, and 4% by other 
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Table III. Prevalence of states O, 1, 2, and 3 BOS 
according to duration of follow-up after 
retransplantation 
Postop. No. of Stage 0 Stage 1 Stage 2 Stage 3 
interval patients (%) (%) (%) (%) 
1 yr 48 79 4 6 11 
2 yr 30 63 10 7 20 
3 yr 16 69 6 0 25 
causes. Interestingly, only 5 of the 80 patients who 
underwent retransplantation because of OB died of 
this complication after operation. 
Predictors of survival by multivariate analysis. 
As shown in Tables I and II, being ambulatory 
immediately before retransplantation was the most 
significant predictor of survival on multivariate anal- 
ysis, followed by reoperation in Europe. Identical 
match of donor-recipient ABO blood group and the 
absence of a cytomegalovirus mismatch, which were 
associated with survival on univariate analysis, did 
not enter the multivariate model. Whereas more 
recent year of retransplantation was a significant 
predictor of survival on multivariate analysis in 
patients with OB,  24 the year of reoperation did not 
significantly influence survival in the 59 patients who 
underwent retransplantation because of other indi- 
cations (Fig. 6). This resulted in the failure of year of 
reoperation toenter the current multivariate model as 
a factor predictive of survival after retransplantation. 
Pulmonary function and recurrence of OB in 
retransplant survivors. Complete, up-to-date FEV 1 
data were available from every retransplant recipi- 
ent who survived at least 1 year after operation. 
Table III shows the BOS stages of patients at yearly 
intervals after retransplantation. Of note is that the 
prevalence of stage 3 (severe) BOS was 11% at 1 
year, 20% at 2 years, and 25% at 3 years after 
retransplantation. There were no significant differ- 
ences in the BOS stage of single versus double lung 
retransplant recipients. Likewise, as shown in Fig. 7, 
there were no statistically significant differences in 
the prevalence of BOS between patients who under- 
went retransplantation because of OB versus those 
who underwent reoperation because of other indi- 
cations (p = 0.49 and 0.45 at 1 and 2 years, 
respectively). Two years after retransplantation, the 
prevalence of stage 3 BOS was 33% in patients who 
underwent reoperation because of OB versus 7% in 
those who underwent retransplantation because of 
graft failure or an airway complication (p = 0.16). 
In the 30 recipients who survived beyond the 
second anniversary of retransplantation, absolute 
FEV 1 values decreased from 1.89 +_ 0.13 L 3 months 
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after reoperation to 1.80 _+ 0.15 L at 1 year (p = 
0.32) and 1.54 + 0.16 L at 2 years (p = 0.006 versus 
baseline postoperative values). There were no sig- 
nificant differences in the rate of decrease of FEV1 
values between patients who underwent single or 
double lung retransplantation. As shown in Fig. 8, 
FEV 1 values did not decrease significantly in the 15 
2-year survivors who underwent retransplantation 
because of acute graft failure or an airway compli- 
cation (p = 0.23, 2-year versus baseline value). 
However, in the 15 survivors Who underwent re- 
transplantation because of OB, FEV 1 values de- 
creased significantly by 2 years after operation (p = 
0.02), although the absolute FEV 1 value was not 
statistically different from that of the non-OB group 
at that time (p = 0.29). 
Discussion 
The results of this study confirm the determinants 
of outcome after pulmonary retransplantation that 
have been noted in previous reports from the regis- 
try.13, 14, 24 Increasing experience with these proce- 
dures in North America and Europe has resulted in 
improved survival after pulmonary retransplanta- 
tion, consonant with the experience in renal aS' 26 and 
hepatic 27-29 retransplantation. Familiarity of individ- 
ual centers with pulmonary retransplantation has 
played a role, inasmuch as the nine institutions that 
reported five or more retransplant procedures ex- 
hibited a trend toward improved patient survival 
compared with that of less experienced centers. 
Whereas reoperation i Europe appeared to confer 
a survival advantage in our previous analysis of 
retransplantation for OB,  24 the influence of conti- 
nent of retransplantation survival has begun to 
wane. This variable was no longer statistically signif- 
icant on univariate analysis and had only a margin- 
ally significant p value on multivariate analysis in 
this study. 
Donor factors at reoperation continued to play 
an important role in determining intermediate- 
term survival after pulmonary retransplantation. 
The presence of a donor-recipient cytomegalovirus 
mismatch was associated with decreased survival on 
univariate analysis. The influence of donor-recipient 
cytomegalovirus matching on survival and on the 
prevalence of OB after primary lung transplantation 
is a subject of controversy, with some studies show- 
ing no discernible ffect 1and other reports indicat- 
ing that the presence of a cytomegalovirus mismatch 
is a highly significant predictor of early and late 
death after operation. 3°Although the immunosup- 
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pressive protocols after retransplantation differed 
among contributing centers, most retransplant re- 
cipients in the registry were administered aug- 
mented immunosuppression perioperatively, which 
perhaps accounted for the increased morbidity and 
mortality from primary cytomegalovirus infection in 
the 18 patients who received a cytomegalovirus- 
mismatched graft. 
Another important finding in this study is that an 
identical match of donor-recipient ABO blood 
group is significantly associated with survival after 
retransplantation. A trend in this direction was 
noted in the first report from the retransplant 
registry in 1993.13 A similar analysis in a larger 
number of patients after primary lung transplanta- 
tion has indicated only a trend toward improved 
survival (p = 0.11) in patients receiving an ABO- 
identical, as opposed to an ABO-compatible, graft 
(personal communication, Ms. Mary Pohl, St. Louis 
International Lung Transplant Registry). The im- 
portance of an identical match of donor-recipient 
ABO blood group in pulmonary retransplantation 
awaits confirmation by the long-term follow-up of a 
larger number of patients with secondary lung grafts. 
The multivariate analysis indicated that the most 
significant predictor of survival after retransplanta- 
tion was the ambulatory status of the recipient 
immediately before reoperation. Patients who were 
able to walk more than 50 m before retransplanta- 
tion were more than twice as likely to be alive at all 
time intervals after operation (adjusted risk ratio of 
death 0.46, p = 0.008). In 1994, almost half of the 
newly registered patients were ambulatory before 
retransplantation, as opposed to 26% in previous 
years. Similarly, very few patients underwent re- 
transplantation i 1993 and 1994 in the setting of 
severe multiorgan failure, which has been shown to 
predict a greater than 90% perioperative mortality 
rate not only in pulmonary retransplantation TM z4 
but also in hepatic retransplantation. 29 These data 
indicate that patient selection for pulmonary re- 
transplantation may be improving, as additional 
experience with these procedures i gained in North 
America and Europe. 
Given the absolute necessity to make optimal use 
of scarce donor lung grafts, it is important to 
determine whether OB or BOS develops in an 
accelerated manner after retransplantation. We are 
aware of only three papers in which the prevalence 
of BOS after primary lung or heart-lung transplan- 
tation has been reported in an actuarial manner. A 
recent study from Stanford indicated that the actu- 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 110, Number 5 
Novick et aL 1411 
arial freedom from "clinical OB" was 71% at 1 year 
and approximately 55% to 60% at 2 and 3 years 
after heart-lung transplantation. 12 In a report from 
the University of North Carolina, the actuarial 
freedom from stages 1, 2, and 3 BOS was 85% to 
90% at 1 year and 60% at 2 years after bilateral lung 
transplantation forcystic fibrosis. 31 In a recent study 
from Hannover, the prevalence of BOS in more 
than 100 patients who underwent primary lung 
transplantation was contrasted with that of 14 pa- 
tients who underwent retransplantation. 21 At i year 
after operation, 88% of primary lung transplant 
recipients and 80% of patients who underwent 
pulmonary retransplantation were free from stage 3 
(severe) BOS. At 2 years, however, 72% of primary 
lung graft recipients were free from stage 3 BOS, 
whereas :only 27% of retransplant recipients had 
avoided this complication. 21 The Hannover group 
regards the development of severe BOS as a failure 
of immunosuppression and has recently switched to 
an FK506-based protocol in its pulmonary retrans- 
plant recipients in an attempt o slow the rate of 
development of BOS in this patient subset. 21 Other 
centers have had a favorable xperience with FK506 
in lung transplantation, 32 although further investi- 
gations are required to determine whether modified 
immunosuppression is capable of reducing the risk 
of graft loss in the intermediate-term after opera- 
tion. 
The pulmonary function test analyses performed 
in this study have determined that the prevalence of 
stages 1, 2, and 3 BOS is almost identical at 1 and 2 
years after retransplantation as in the previously 
noted series of primary lung transplantation. 12' 21, 31 
Our 80% rate of freedom from stage 3 BOS 2 years 
after retransplantation compares favorably with the 
freedom from stage 3 BOS in recipients of primary 
lung grafts in the Hannover study. 21 Furthermore, 
our 63% rate of freedom from stages 1, 2, and 3 
BOS at 2 years is similar to the 60% freedom from 
the same BOS stages in the North Carolina experi- 
ence. 31 Current evidence, therefore, indicates that 
in patents who undergo pulmonary retransplanta- 
tion BOS deveiops with a similar prevalence and 
intensity as in recipients of primary lung grafts. 
Although in some patients rapidly progressive BOS 
develops after retransplantation, the majority of 
retranspl~nt survivors have acceptable pulmonary 
function in the intermediate-term after operation. 
Detailed anatysis of patient subgroups has con- 
firmed that pulmonary function declines at a similar 
I 
rate in single and bilateral lung retransplant recipi- 
ents. Interestingly, FEV 1 values decreased signifi- 
cantly by 2 years after operation in patients who 
underwent retransplantation because of OB, but not 
in patients who underwent retransplantation be- 
cause of acute graft failure or an airway complica- 
tion. Although the differences in FEV 1 and the 
prevalence of stage 3 BOS were not statistically 
significant between these two patient groups at 2 
years, it is possible that with further patient fol- 
low-up and additional patient accrual statistically 
significant differences will be realized. These results 
underline the importance of research on alternative 
immunosuppressive protocols in primary and sec- 
ondary lung transplantation, so that the prevalence 
of BOS and its recurrence rate after retransplanta- 
tion can be minimized. 
In summary, survival after pulmonary retrans- 
plantation is improving because of increasing expe- 
rience and better patient selection. The goal of the 
retransplant registry has been to accelerate this 
trend by determining the factors associated with 
survival and, ultimately, with excellent graft function 
after retransplantation. Current evidence indicates 
that optimal results may be anticipated in ambula- 
tory candidates who receive an ABO-identical graft 
that is matched for cytomegalovirus status. Retrans- 
plant recipients who survive the first 3 postoperative 
months have a medium-term prognosis imilar to 
that of patients with first-time lung transplants. 
Efforts to minimize early mortality from infection 
should improve further the results of retransplanta- 
tion and justify the continued performance of these 
procedures in highly selected patients. 
We thank the contributing thoracic surgeons, pulmo- 
nary medicine physicians, and recipient coordinators who 
have participated in the pulmonary etransplant registry. 
We also acknowledge the assistance ofHeather Motloch 
in manuscript reparation a d of Theresa Novick, MSc, in 
data collection and analysis. 
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Appendix 
Contributing centers, thoracic surgeons, pulmonolo- 
gists, and coordinators are as follows: Allegemeine Kran- 
kenhaus, Vienna, Austria; Walter Klepetko, Bernhard 
Schlechta, Abelheid End (18 patients). Medizinische 
Hochschule Hannover, Hannover, Germany; Hans- 
Joachim Schgfers (14 patients). Presbyterian University 
Hospital, Pittsburgh, Pa.; Bartley Griffith, Robert Hardesty, 
Ann Lee, Debbie Opacic (12 patients). H6pital Beau- 
jon, Clichy, France; Bernard Andr6assian, Jean-Pierre 
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Duchatelle (10 patients). Baylor-Methodist Hospital, Hous- 
ton, Tex.; Adaani Frost, George Noon, H. David Short, 
Janine O'Leary (10 patients). Toronto Hospital, Toronto, 
Ontario, Canada; Tim Winton, Janet Maurer, Massina Sca- 
vuzzo, Louise Won (9 patients). University of Minnesota 
Health Center, Minneapolis, Minn.; R. Morton Bolman, 
Marshall Hertz, Beth Dosland (6 patients). Loyola Univer- 
sity Medical Center, Maywood, Ill.; James Houck, Edward 
Garrity (5 patients). St. Louis Children's Hospital, St. Louis, 
Mo.; Thomas Spray, George Mallory (5 patients). Washing- 
ton University-Barnes Hospital, St. Louis, Mo.; Alec Patter- 
son, Joel Cooper, Mary Pohl (4 patients). University of 
North Carolina Medical Center, Chapel Hill, N.C.; Tom 
Egan, Ellen Cairns (4 patients). Stanford University Medical 
Center, Stanford, Calif.; Bruce Reitz, Tom Bnrdon (3 pa- 
tients). University of Michigan Medical Center, Ann Arbor, 
Mich.; Michael Deeb, Ros Florn (3 patients). University of 
Texas Medical Center, San Antonio, Tex.; John Calhoon, 
Kent Trinkle (3 patients). Montreal General Hospital, Mon- 
treal, Quebec, Canada; Hani Shennib (3 patients). Freeman 
Hospital, Newcastle-upon-Tyne, England; John Dark, Paul 
Corris (3 patients). Rikshospitalet, Oslo, Norway; Odd Gel- 
ran, Oystein Bjortuft (2 patients). University of Iowa Hospi- 
tal, Iowa City, Iowa; Louis Lanza (2 patients). University of 
Pennsylvania Hospital, Philadelphia, Pa.; Larry Kaiser, 
Nancy Blumenthal, Angela Wurster (2 patients). Vanderbilt 
University Medical Center, Nashville, Tenn.; Jim Loyd, Bill 
Frist (2 patients). University of Wisconsin Medical Center, 
Madison, Wis.; Robert Love, Debbie Welter (2 patients). 
Papworth Hospital, Cambridge, England; John Wallwork (2 
patients). H6pital d'Enfants de la Timone, Marseille, 
France; Dominique Metras (2 patients). H6pital Xavier- 
Arnozan, Pessac, France; Louis Couraud, Claire Dromer (2 
patients). Klinikum Grosshadern, Munich, Germany; Bruno 
Reichart, Florio Wagner (2 patients). Centre for Health 
Sciences, Winnipeg, Manitoba, Canada; Wayne Kepron, 
Helmut Unruh (1 patient). Brigham and Women's Hospital, 
Boston, Mass.; Stephen Mentzer, David Sugarbaker, Carol 
Coakley (1 patient). University of Virginia Health Sciences 
Center, Charlottesville, Va.; Curtis Tribble, John Truwit, 
Margaret Ball (1 patient). H6pital Erasme, Brussels, Bel- 
gium; Martine Antoine, Marc Estenne (1 patient). Univer- 
sity Hospita], Rigshospitalet; Gosta Pettersson, Ulrik Gerner 
Svendsen (! patient). Helsinki University Central Hospital, 
Helsinki, Finland; Ari Harjula (1 patient). Centre Medico- 
Chirurgical Foch, Suresnes, France; Alain Bisson (1 patient). 
Academisch Ziekenhuis Groningen, Groningen, The Neth- 
erlands; Wim de Boer (1 patient). Universitfitsspital Zfirich, 
Zfirich, Switzerland; Walter Weder (1 patient). 
Discussion 
Dr. C. G. A. McGregor (Rochester, Minn.). I would like 
to congratulate Dr. Novick and his colleagues for success- 
fully forming the pulmonary retransplant registry. Clearly, 
no individual center develops enough experience with 
such relatively unusual techniques to be able to draw 
meaningful conclusions as to optimal management. For 
example, perhaps only 15 of the 77 lung transplant centers 
in the United States perform more than 10 transplants per 
year. 
I would encourage members of the Association to 
pursue similar efforts whether as registries of multicenter 
studies in pursuit of knowledge as to the best management 
of other rare clinical challenges in cardiothoracic trans- 
plantation. Examples that come to mind include cardiac 
transplantation for amyloid disease or cardiac tumors and 
pulmonary transplantation for systemic ollagen diseases; 
there are many other examples. 
Pulmonary retransplant candidates comprise a group of 
patients with extremely challenging conditions in that they 
have received recurrent heavy immunosuppressive ther- 
apy for treatment of OB or recalcitrant rejection including 
steroids, cytolytic therapy, and sometimes total lymphoid 
irradiation. These patients are, therefore, in profoundly 
immunosuppressed conditions and not in a good state for 
retransplantation in terms of the likelihood of infection 
and perhaps the development of posttransplant lympho- 
proliferative disorders. It is no surprise, therefore, that 
56% of the early deaths in this series were caused by 
infection. Only 29% of the retransplant recipients whose 
results are presented in this paper were ambulatory and 
half were ventilator dependent. Although the survival of 
45% at 1 year is disappointing, it is important to note that 
those patients who survived for 90 days after operation 
had a survival thereafter comparable with that of primary 
lung transplant recipients. 
It is also interesting that the interval between transplan- 
tation and retransplantation a d the reason for retrans- 
plantation did not have an impact on survival, unlike the 
situation in heart retransplantation in which early retrans- 
plantation, which is commonly necessitated by recalcitrant 
rejection, has a 1-year survival approximately half of that 
for late retransplantation, which is commonly done be- 
cause of accelerated transplant atherosclerosis. 
This paper informs us that the preoperative status of 
the patient as reflected by ambulation immediately before 
retransplantation is the critical factor in a successful 
outcome. If, with this important information, we can 
reduce early mortality, then we know from this presenta- 
tion that the rate of recurrence of OB will be no greater 
than that after a primary transplant and that satisfactory 
lung function will be achieved. 
I would like to ask Dr. Novick the following three 
questions. First, previous reports from the registry indi- 
cated that removal of the previously transplanted lung was 
important, but the current report suggests this is no longer 
true. Is this change simply a reflection of more numbers in 
the registry? Second, there seems to be a paradox in that 
being ambulatory is important in survival, and yet being 
ventilator dependent is not. Can you explain this? Third, 
can you comment on the contrast between the indication 
and time interval before retransplantation not being a 
factor in survival in pulmonary retransplantation com- 
pared with the situation in heart retransplantation? 
Dr. Noviek. In 1993 I presented a paper on 33 patients 
who underwent retransplantation because of OB. The 
survival of patients without an old, retained contralateral 
graft was significantly better than that of patients with an 
old contralateral graft. Two years have gone by, the 
number of patients in the registry has increased fourfold 
(to 139), and patient selection and postoperative treat- 
ment have improved. Likely, increased patient accrual to 
the pulmonary retransplant registry and these other fac- 
tors have muted the importance of the presence of an old 
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contralateral graft as a predictor of poor outcome after 
retransplantation. 
There was no difference in survival between the 70 
patients who were receiving ventilator support and the 
69 patients who were not receiving ventilator support 
before retransplantation. Of the 70 patients who were 
on a ventilator, however, 33 were ambulatory; they were 
able to walk at least 50 m with assistance from the 
nursing and physiotherapy staff. Thus, if the patients 
are rehabilitated in every other way except for the 
ventilatory status before retransplantation, a d if they 
survive the perioperative period, in all likelihood they 
will do well. 
Finally, concerning the interval between transplant op- 
erations, it is true that in cardiac retransplantation an 
interval of greater than 6 months correlates with a suc- 
cessful outcome. When analyzed as a continuous variable 
after pulmonary retransplantation, there is no relationship 
between the interval between transplants and survival. 
Dr. Alvaro Montoya (Chicago, Ill.). At Loyola Univer- 
sity in Chicago we have done 135 lung transplants since 
1991. Seven of these patients required retransplantation. 
We had four survivors. One of these survivors was a 
21-year-old girl with cystic fibrosis in which OB developed. 
I elected to do a retransplant in her case. I retransplanted 
the heart and lung because of clinical feasibilities. OB 
developed in the new transplanted lungs 3 mouths after 
retransplantation a d she died. We had been debating 
about doing a second retransplantation, but she died 
before we came to a conclusion. 
We now have six patients on the waiting list for 
retransplantation. O e of these is a 32-year-old marathon 
runner who received ouble-lung transplantation because 
of alveolar cell carcinoma. Now he needs a retransplant 
and we are debating about whether to do it. 
We are committed to these patients. For their care we 
performed transplantation e time; maybe we should 
perform retransPlantation f it is required. My question is 
simple. Should we continue to do retransplants? We do 
not retransplant hearts. I have asked why and the answer 
was, we do not have donors. Should be continue to do 
retransplants on patients with lung disease? 
Dr. Noviek. In brief, I believe that as a minimum a 
pulmonary retransplant candidate should meet the same 
criteria as a first-time lung transplant candidate and 
perhaps be even more highly selected. Our findings, which 
show satisfactory results in the intermediate term of 
90-day postoperative survivors of retransplantation, indi- 
cate that we should still b e retransplanting lungs, but that 
patient selection should be further efined. 
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